Testing a thyroid hormone drug with chemo for relapsed medulloblastoma
Treatments studied
Part of Cancer clinical trials.
This trial tests whether adding a thyroid hormone (liothyronine) to a standard chemotherapy combination (bevacizumab, irinotecan, temozolomide) can help children and young adults with medulloblastoma that has come back after initial treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have medulloblastoma that has returned or worsened after standard therapy.
- You are between 1 and 25 years old.
- You have disease visible on MRI or in spinal fluid (cf-DNA positive).
- You have adequate organ function (blood counts, kidney, liver, heart, and adrenal glands).
- You have not had prior treatment with exactly the same chemotherapy combination tested here (BIT regimen).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests how doctors choose treatment for infants and young children with newly diagnosed medulloblastoma, based on MRI/CSF staging and lab testing of the tumor. It may help by matching therapy intensity to the child’s specific risk level and tumor type.
This trial tests a treatment that targets tumor blood-vessel growth to slow or shrink relapsed/progressive brain tumors in children. It may help if standard options are no longer working.
This trial tests a combination of chemotherapy drugs (topotecan given into the spine plus maintenance chemo) for children under 6 with high-risk embryonal brain tumors. The goal is to see if this approach can improve outcomes after initial treatment.
This Phase 1 study tests a combination treatment (ibrutinib plus indoximod along with chemotherapy) for children with brain tumors that have come back or are hard to treat. It may help shrink active tumor or control the disease when standard treatments can’t cure it.
This study tests a personalized treatment plan for children and young adults whose medulloblastoma or ependymoma has come back. It aims to guide doctors using new tissue from surgery or biopsy after earlier treatments are fully finished.
This trial compares two standard treatments for a type of brain tumor called SHH-activated medulloblastoma in children under 5. The goal is to see which treatment better protects thinking and learning skills over time.
Hear when a new Medulloblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.